Literature DB >> 6529534

Serum protein binding and the role of increased alpha 1-acid glycoprotein in moderately obese male subjects.

I H Benedek, R A Blouin, P J McNamara.   

Abstract

Serum protein and lipid concentrations as well as the serum protein binding of propranolol, diazepam and phenytoin were measured in normal weight and obese volunteers. Concentrations of alpha 1-acid glycoprotein (AAG) in the obese subjects were double that of the lean controls. Conversely, concentrations of high density lipoproteins (HDL) were decreased in the obese group. The serum binding of propranolol was increased in the obese subjects and correlated with serum AAG concentrations. Diazepam binding was slightly decreased in the obese as a result of lower serum albumin concentrations and elevated free fatty acids. The binding of phenytoin was comparable in all of the volunteers. These findings point out some of the complex pathophysiologic changes associated with obesity which may in turn influence drug disposition and hence drug therapy in the obese patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6529534      PMCID: PMC1463695          DOI: 10.1111/j.1365-2125.1984.tb02567.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

2.  Kinetics of induction of alpha 1-acid glycoprotein.

Authors:  G A Ricca; J W McLean; J M Taylor
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

3.  Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Authors:  P A Routledge; D G Shand; A Barchowsky; G Wagner; W W Stargel
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  Alterations in drug distribution and clearance due to obesity.

Authors:  D R Abernethy; D J Greenblatt; M Divoll; J S Harmatz; R I Shader
Journal:  J Pharmacol Exp Ther       Date:  1981-06       Impact factor: 4.030

5.  A sensitive method for the determination of free fatty acids in plasma.

Authors:  W T Hron; L A Menahan
Journal:  J Lipid Res       Date:  1981-02       Impact factor: 5.922

6.  Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Ann Intern Med       Date:  1977-10       Impact factor: 25.391

7.  Diazepam plasma binding in the perinatal period: influence of nonesterified fatty acids.

Authors:  M J Ridd; K F Brown; R G Moore; W G McBride; R L Nation
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Obesity, lipids, and glucose intolerance. The Framingham Study.

Authors:  W B Kannel; T Gordon; W P Castelli
Journal:  Am J Clin Nutr       Date:  1979-06       Impact factor: 7.045

9.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

Review 10.  Pharmacokinetics of drugs in obesity.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

View more
  25 in total

Review 1.  Effects of obesity on pharmacokinetics implications for drug therapy.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Orosomucoid serum concentrations and fat depot-specific mRNA and protein expression in humans.

Authors:  Assim A Alfadda; Sumbul Fatma; M Azhar Chishti; Mohammed Y Al-Naami; Ruba Elawad; Carmen Deanna O Mendoza; Hyunsun Jo; Yun Sok Lee
Journal:  Mol Cells       Date:  2011-11-29       Impact factor: 5.034

Review 5.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of drugs in obesity. An update.

Authors:  G Cheymol
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 7.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Maternal obesity alters feto-placental cytochrome P4501A1 activity.

Authors:  B N DuBois; P O'Tierney-Ginn; J Pearson; J E Friedman; K Thornburg; G Cherala
Journal:  Placenta       Date:  2012-10-06       Impact factor: 3.481

Review 9.  Body mass index and the efficacy of acid-mediating agents for GERD.

Authors:  Brian C Jacobson
Journal:  Dig Dis Sci       Date:  2008-07-16       Impact factor: 3.199

Review 10.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.